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Abstract:  South Africa, like many other developing countries, stands to benefit from novel diagnostics and drugs 
developed by pharmacogenomics guidance due to high prevalence of disease burden in the region. This includes both 
communicable (e.g., HIV/AIDS and tuberculosis) and non-communicable (e.g., diabetes and cardiovascular) diseases. For 
example, although only 0.7% of the world’s population lives in South Africa, the country carries 17% of the global 
HIV/AIDS burden and 5% of the global tuberculosis burden. Nobel Peace Prize Laureate Archbishop Emeritus Desmond 
Tutu has coined the term Rainbow Nation, referring to a land of wealth in its many diverse peoples and cultures. It is now 
timely and necessary to reflect on how best to approach new genomics biotechnologies in a manner that carefully 
considers the public health needs and extant disease burden in the region. The aim of this paper is to document and review 
the advances in pharmacogenomics in South Africa and importantly, to evaluate the direction that future research should 
take. Previous research has shown that the populations in South Africa exhibit unique allele frequencies and novel genetic 
variation in pharmacogenetically relevant genes, often differing from other African and global populations. The high level 
of genetic diversity, low linkage disequilibrium and the presence of rare variants in these populations question the 
feasibility of the use of current commercially available genotyping platforms, and may partially account for genotype-
phenotype discordance observed in past studies. However, the employment of high throughput technologies for genomic 
research, within the context of large clinical trials, combined with interdisciplinary studies and appropriate regulatory 
guidelines, should aid in acceleration of pharmacogenomic discoveries in high priority therapeutic areas in South Africa. 
Finally, we suggest that projects such as the H3Africa Initiative, the SAHGP and PGENI should play an integral role  
in the coordination of genomic research in South Africa, but also other African countries, by providing infrastructure  
and capital to local researchers, as well as providing aid in addressing the computational and statistical bottlenecks 
encountered at present.  
Keywords: Disease burden, ELSI, genomic technologies, global health, personalized medicine, pharmacogenomics, population 
genetic diversity, South Africa. 
1. INTRODUCTION 
  Situated at the tip of the African continent, South Africa 
is home to an eclectic array of cultures, illustrated by the 
eleven official languages recognized in the country. Today, 
South Africa is acknowledged for its impressive political 
change, progress and development [1], but the country has  
a complex history of free and forced migration and immigra- 
tion, oppression and liberation. In an assessment of South 
Africa’s health status and systems, Coovadia et al. [2] point 
out that the challenges that South Africa is currently facing 
are deeply rooted in this unique history.  
  At present South Africa faces a high burden of both 
communicable and non-communicable diseases, high mater- 
nal and child mortality, as well as injury and violence related 
deaths [2]. Although only 0.7% of the world’s population 
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lives in South Africa, the country carries 17% of the global 
Human Immunodeficiency Virus/Acquired Immunodeficiency 
Syndrome (HIV/AIDS) burden and 5% of the global 
tuberculosis (TB) burden [3, 4]. HIV/AIDS is also one of the 
leading causes of maternal and child deaths and South Africa 
is one of only twelve countries for which the mortality rate 
of children has increased since the Millennium Development 
Goals baseline in 1990 [5, 6]. The most prevalent non-
communicable diseases in South Africa are cardiovascular 
diseases, diabetes mellitus, respiratory diseases, cancers and 
neuropsychiatric disorders [7]. The rise in these diseases is 
associated with an increase in risk factors due to demo- 
graphic changes over the past few years, and their distribu- 
tion largely reflects socioeconomic disparities between 
communities [7]. This high burden of infectious and chronic 
diseases results in a health system that is continuously under-
resourced. Accordingly, South Africa’s per capita health 
burden is the highest of any middle-income country in the 
world and its health outcomes are often worse than lower 
income countries [2, 8].  192    Current Pharmacogenomics and Personalized Medicine, 2011, Vol. 9, No. 3  Warnich et al. 
  Interventions aimed at addressing the burden of HIV/ 
AIDS, TB and other communicable and non-communicable 
diseases are multi-faceted, but rely heavily on prevention and 
treatment, which in turn entails drug therapy. Firstly, it is 
necessary that drug regimens are accessible to all. Although 
some limitations still exist, free anti-retroviral therapy (ART) 
has been available in the public health system since 2003, 
and has dramatically improved the survival of HIV-infected 
patients [3]. With a public health system that is already under 
enormous pressure, it is therefore imperative that drug 
treatment plans be efficient and cost-effective. Treatment, 
however, is frequently associated with toxicity, which 
impacts on its efficacy and costs [9]. It is well known that 
adverse drug reactions (ADRs) are responsible for a notable 
number of hospitalizations, and fatal ADRs are among the 
leading causes of death in developed countries [10, 11]. In 
South Africa, ADRs are reported to occur in 14% of 
hospitalized patients, as opposed to the 6.7% reported 
internationally, with a five to ten times higher fatality rate 
[12]. This study also showed that the HIV/AIDS and TB 
epidemics have a significant impact on the epidemiology of 
ADRs in South Africa, often due to polypharmacy. Not only 
do ADRs contribute to the financial burden on the health 
system, but they also contribute to poor patient compliance, 
with the subsequent emergence of drug resistant pathogens, 
and the continuation of epidemics [13-15]. These data hold 
major implications for the delivery of health care services in 
South Africa, especially when considering chronic illnesses, 
such as HIV/AIDs, that require lifelong treatment.  
  Pharmacogenomic applications (as seen in the broader 
context of the field, [16]) hold the promise of using genome-
based technologies to improve health by the prevention or 
effective treatment of disease. Even in the developing world, 
pharmacogenomics can serve to improve a country’s “ability 
to respond to local disease threats” and to “make better 
policy decisions regarding the most optimal interventions 
within their own health care delivery systems” [16]. 
Specifically, the implementation of pharmacogenomics in 
the treatment of HIV/AIDS should be a priority in South 
Africa. Unfortunately, very few clinically validated ART 
pharmacogenetic markers are available, and none, to our 
knowledge, have been validated in the context of South 
African populations and treatment regimes. Currently no 
pharmacogenetic test is indicated in the South African ART 
guidelines [17]. Furthermore, some of the available bio- 
markers may not have so much utility in the South African 
setting. For example, although HLA-B*5701 screening to 
identify patients who are at risk to develop abacavir 
hypersensitivity syndrome has been shown to be cost-
effective and has been included in treatment guidelines and 
drug labels in the United States (US) and Europe, this allele 
seems to be rare in certain African populations [18-20]. 
Additionally, in South Africa, abacavir is only included in 
the guidelines for treatment of infants and children and is not 
one of the most frequently prescribed drugs. Therefore, 
studies examining the effect of variants in genes involved in 
the metabolism, transport and absorption of drugs included 
in the current first or second line ART regimen in South 
Africa [17], such as CYP2B6 that is involved in the 
metabolism of efavirenz and nevirapine, are required.  
  Despite the fact that pharmacogenomics was specifically 
highlighted in The National Biotechnology Strategy for 
South Africa [21] and that the development of technology 
platforms for pharmaceutical industries is advocated in a Ten 
Year Innovation Plan by the South African Department of 
Science and Technology (DST) [21], new developments in 
this field within the country have been slow. For example, 
the large scale genotyping project to profile the South 
African populations has not been fully realized yet, neither 
has a central bio-repository or database been established 
[22].  
  The current genomic challenge is to ascertain the genetic 
diversity in our understudied populations, to understand 
genotype-environment interactions, and to translate this 
knowledge into clinical applications that can be applied in 
public health care. This report provides an overview of the 
populations of South Africa and demonstrates the unique 
genetic and pharmocogenetic profiles of some of these 
populations as revealed by a limited number of studies. The 
paper also discusses the ethical, social and legal frameworks 
that are in place or are being developed, and points to some 
of the opportunities and challenges that can impact on the 
realization of the full benefits of pharmacogenomics to 
improve health in South Africa.  
2. THE RAINBOW NATION 
  Nobel Peace Prize Laureate Archbishop Emeritus 
Desmond Tutu has coined the term Rainbow Nation, 
referring to a land of wealth in its many diverse peoples and 
cultures. It is now timely and necessary to reflect on how 
best to approach new genomics biotechnologies in a manner 
that carefully considers the public health needs and extant 
disease burden in the region.  
  The interesting and diverse history of South Africa is 
reflected in the genomes of the nearly 50 million individuals 
residing within the country [4]. The first modern humans in 
southern Africa were the Khoisan-speakers and Bantu-
speakers, who arrived approximately 20,000 and 4,000 years 
ago, respectively [23]. A few thousand years later, European 
settlers landed in South Africa, the most noteworthy of 
which were the Dutch in 1652 and the British around the 
start of the 19
th century. Accompanying these early settlers 
were slaves, political prisoners, laborers and traders, 
originating predominantly from East Africa and Asia   
[24, 25]. This varied history has resulted in South African 
populations which range from ancient and genetically 
diverse, to highly admixed, to recent and homogenous. 
Broadly speaking, the most recent South African population 
census has divided the Rainbow Nation into four population 
groups, namely Africans, Whites (Caucasians), Coloureds 
(Mixed Ancestry) and Indians/Asians, which constitute 
79.4%, 9.2%, 8.8% and 2.6% of the total population, 
respectively [4]. These broad population census definitions, 
however, only hint at the number of diverse ethnic groups 
residing within South Africa.  
  The black African people of South Africa are descendants 
of ancient and diverse populations. Africa is believed to be 
the site of origin of the earliest reported humans and African 
populations are consequently renowned for their consi- 
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because of their exposure to varying diets, climates, 
infectious diseases and geography [26, 27]. Southern African 
populations, specifically, have been shown to exhibit the 
highest level of genetic diversity and the greatest within-
population diversity. For example, the differences observed 
between genomes of two southern African Khoisan 
individuals living within walking distance from one another 
were reported to be greater than the differences observed 
between Asian and European individuals living on different 
continents [28].  
  Individuals with African ancestry that reside in South 
Africa today have reportedly arisen from two main groups: 
the Bantu from West Central Africa and the Khoisan, who 
are one of the most ancient populations, from eastern Africa 
[23, 29]. Although the Bantu and Khoisan are discernable 
from one another, over time, admixture has occurred 
between these two groups [25, 30, 31], which is reflected in 
the clicks present in some of the Bantu languages spoken in 
South Africa (see Table 1 for the official South African 
languages). Almost a quarter (23.8%) of the population 
indicated isiZulu as their home language in the 2001 Census 
[32]. The second largest home language group was isiXhosa 
(17.6%), while the five least spoken home languages 
(Sesotho, Xitsonga, siSwati, Tshivenda and isiNdebele) 
collectively comprised 19%. A study performed by Lane   
et al. [33], examining autosomal short tandem repeats   
and mitochondrial DNA (mtDNA) variation, showed that 
although there is a high level of within-group genetic 
diversity present in the different Bantu populations, the level 
of relatedness between the groups suggests a common 
ancestral population. Even so, the different linguistic groups 
can be divided up into sub-groups, according to the 
examined autosomal and mtDNA variation, which roughly 
correspond to their historical geographic location within 
South Africa (Fig. 1). 
  While the Africans residing within South Africa 
represent ancient populations, the South African Coloured or 
Mixed Ancestry population, which reportedly exhibits the 
highest level of admixture worldwide [34], is estimated to 
have arisen only about 350 years ago [25]. The term 
Coloured, which is the preferred term used by the members 
of the population themselves [25], was only introduced in 
1808 with the abolishment of slavery [35]. The origin of this 
unique population group can largely be attributed to South 
Africa’s position in major trade routes, which attracted 
individuals from all over the world. Genetic studies 
examining variation on a genome-wide level have shown 
that this population group has ancestry contributions from at 
least four different sources, namely Xhosa, Khoisan, 
European and Asian [25, 34, 36], the largest of which stems 
from the Khoisan [25, 30, 36, 37]. Considerable variation, 
however, can exist between individuals regarding ancestry 
proportions [34, 36]. Additionally, recent studies have shown 
that there was a gender biased gene flow, which is in 
accordance with the history of South Africa. This gene flow 
suggests that the majority of the Coloured population arose 
from male dominated European settlers and female 
slaves/natives [25, 37].  
  Whereas African and Coloured populations represent 
genetically diverse and admixed population groups, 
Caucasian and Indian South Africans are relatively 
homogenous in nature. This being said, although most of 
South African Caucasian and Indian ancestry has been 
identified as originating from European or Indian ancestors, 
small amounts of gene flow from Africans have been 
detected in both populations [30, 38, 39]. Focusing on the 
Caucasians, one of the earliest groups to take up residence in 
South Africa were Dutch East India Company settlers, who 
set up a refreshment station in the Cape in 1652. This group 
of individuals gave rise to the Afrikaner population, which is 
Table 1.  Distribution of South African Home Languages within the Country, Based on the 2001 Population Census* [32] 
Official South African Languages  Number of First Home Language Individuals  Percentage of Total South African Population 
IsiZulu 10,677,305  23.8 
IsiXhosa 7,907,153  17.6 
Afrikaans 5,983,426  13.3 
Sepedi 4,208,980  9.4 
Setswana 3,677,016  8.2 
English 3,673,203  8.2 
Sesotho 3,555,186  7.9 
Xitsonga 1,992,207  4.4 
SiSwati 1,194,430  2.7 
Tshivenda 1,021,757  2.3 
IsiNdebele 711,821  1.6 
Other 217,293  0.5 
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homogenous as a result of a small founding population, in 
combination with a rapid population increase [24]. The 
homogeneity of this population group is reflected in the high 
level of linkage disequilibrium (LD) observed [40] and the 
high frequency of rare disorders, such as variegate porphyria 
and familial hypercholesterolemia [24]. Similarly, the South 
African Indian population has a relatively high incidence   
of insulin resistance, which is coupled to increased risks   
for type 2 diabetes and ischemic heart disease [41]. The 
observed homogeneity in the Indian population may in   
part be attributed to strict religious customs, which have 
traditionally prevented marriage outside this ethnic group, 
and is reflected in the diminished mtDNA variation in   
these individuals, when compared to Indians living in Nepal 
[38].  
  Although genetic analyses of the diverse populations 
living in South Africa may prove challenging, there are also 
several unique benefits that these populations may offer to 
future genomic studies. Thus, the genetic diversity, 
homogeneity and admixture of these population groups 
should be utilized to elucidate the genetic factors contribut- 
ing to complex disorders and traits, including drug response.  
3. GENETIC VARIATION IN PHARMACOGENETI- 
CALLY RELEVANT GENES (PHARMACOGENES) 
IN SOUTH AFRICAN POPULATIONS 
  Current knowledge on the genetic diversity of South 
Africa’s diverse populations, and specifically pharmaco- 
genetic diversity, is based on a limited number of studies that 
have focused on candidate genes, using relatively small 
sample sizes. In the following section we will highlight a few 
of these studies. The data obtained thus far indicate that   
our populations demonstrate unique genetic profiles that 
include novel and rare variants, with allele frequencies often 
differing from each other and other African populations. It is 
not within the scope of this paper, however, to provide an 
extensive and complete overview of all studies that have 
been performed to date. Examples of frequencies of the   
most clinically important pharmacogene variants detected in 
South African populations are shown in Table 2. For a more 
expanded comparison of allelic variation in 12 genes that 
influence drug treatment, using two South African 
populations, the Xhosa and the Coloured, the reader is 
referred to a recent study by Ikediobi et al. [42]. 
3.1. Cytochrome P450 (CYP) Genes 
  To date, most studies on important pharmacogenes in 
South African populations have been conducted on genes 
encoding the major drug metabolizer family, the Cytochrome 
P450 (CYP) enzymes. The CYP enzymes play an important 
role in the Phase 1 metabolism of endogenous and exo- 
genous compounds, including the majority of clinically 
administered drugs. Specific genetic polymorphisms or 
haplotypes in these genes define specific alleles [43]. 
Different alleles are often known to have different effects   
on enzyme activity and individuals are classified as poor 
(PM), extensive (EM), intermediate (IM) or ultrarapid (UM) 
metabolizers for specific enzymes.  
CYP2B6 
  The CYP2 family includes some of the most important 
metabolizing enzymes. CYP2B6 is the only significant 
enzyme in the CYP2B subfamily and although it accounts 
for <10% of the total human hepatic P450 content, it 
metabolizes numerous substrates for a variety of clinical 
conditions. CYP2B6 is of special importance in the South 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The approximate historical location of the different African (Bantu) linguistic population groups within South Africa (adapted from 
[33]). 
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Table 2. Frequency Comparisons of Clinically Relevant Alleles Detected in South African Populations 
Gene  South African Population  Clinically Relevant Alleles  Reference 
Cytochrome P450 Genes 
   *6            
Venda (n=81)  0.36            [47]  African 
Xhosa HIV patients (n=112)  0.32            [46] 
CYP2B6 
Coloured  HIV patients (n=70)  0.30            [46] 
   *2 *3          
Unspecified (n=100)  0.00  0.01          [54] 
CYP2C9 
African 
Venda (n=9)  0.00  0.00          [56] 
   *2 *3  *17        
Venda  (n=81)  0.21 0.00  NG      [47]  African 
Xhosa (n=100)  0.21  0.00  0.10        [64] 
CYP2C19 
Coloured (n=75)  0.17  0.07  0.14        [64] 
   *2xN *4  *5  *10  *17  *29   
Venda (n=81)  NG  0.03  0.05  0.12  0.24  0.06  [47]  African 
Xhosa (n=53)  0.03  0.04  0.14  0.02  0.13  0.13  [70] 
CYP2D6
1 
Coloured (n=99)  0.01  0.07  0.17  0.03  0.13 0.05  [69] 
   *1B            
Mainly Zulu (n=110)  0.84            [76]  African 
Xhosa HIV patients (n=112)  0.78            [46] 
Caucasian (n=141)  0.04            [80] 
HIV patients (n=70)  0.57            [46]  Coloured 
(n=146) 0.21            [80] 
CYP3A4 
Indian (n=103)  0.11            [76] 
   *3 *6  *7        
African Xhosa  (n=142)  0.14  0.21  0.01        [84] 
Caucasian  (n=141)  0.94 NG  NG      [80] 
CYP3A5 
Coloured (n=99)  0.59  0.12  0.00        [84] 
Other Pharmacogenes 
   1236C>T 2677G>T/A  3435C>T        
Mainly Zulu (n=110)  NG  NG  0.14        [76]  African 
Xhosa HIV patients (n=112)  0.13  0.03  0.10        [46] 
Coloured  HIV patients (n=70)  0.24  0.18  0.21        [46] 
ABCB1 
Indian (n=103)  NG  NG  0.58        [76] 
   *3 *4  *10  *11,*14-*16       NAT1 
African  Mainly Tswana (n=101)  0.01  0.49  0.51  0.00      [89] 
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Table. 2 contd…. 
Gene  South African Population  Clinically Relevant Alleles  Reference 
Other Pharmacogenes 
   *4 *5  *6  *7  *14    
Mainly Tswana (n=101)  0.13  0.32  0.19  0.00  0.09    [89] 
Venda (n=192)  0.23  0.39  0.22  0.05  0.11    [90] 
African 
Xhosa (n=120)  NG  0.20  0.15  0.02  0.03    [91] 
NAT2 
Coloured (n=85)  NG  0.25  0.11  0.03  0.05   [91] 
   *2 *3A  *3C        
African Unspecified  (n=200)  0.00  0.00  0.03        [94] 
Caucasian (n=65)  0.00  0.05  0.02        [94] 
TPMT 
Coloured (n=200)  0.00  0.00  0.03        [94] 
   -1639 G>A  1173C>T  3730 G>A         VKORC1 
African Unspecified  (n=100)  NG  NG  0.43        [54] 
In those cases where the same population was examined by more than one study, the frequency data from the most comprehensive study was used. 
1: For those studies which genotyped the CYP2D6 duplication, those duplications other than *2xN were pooled with the relevant single copy alleles. 
NG: Not genotyped. 
African context as it is required for the metabolism of two of 
the drugs used in first line ART of HIV/AIDS, efavirenz and 
nevirapine, as well as the antituberculosis agent rifampicin 
[44].  
  Genetic variants, such as CYP2B6:516G>T and 785A>G, 
defining the allele CYP2B6*6, have been associated with 
ADRs of efavirenz treatment and are more common in 
Africans than in Caucasians [44]. CYP2B6*6 was detected in 
Coloured and Xhosa patients with HIV [45, 46], and in a 
Venda cohort [47] at frequencies that ranged from 30-36%. 
This allele was found at a frequency of 37% in the Batswana 
[48], but at higher frequencies (49%) in Ghanaians and 
Zimbabweans [49, 50]. Cohen et al. [51] reported that 
although the CYP2B6*6 allele is common in South African 
patients on simultaneous rifampicin-based antitubercular 
therapy and ART (including efavirenz), no dosage adjust- 
ments were required. CYP2B6*6 was associated with high 
efavirenz concentrations and severe sleep disturbance in this 
cohort.  
CYP2C9 and VKORC1 
  Members of the CYP2C enzyme subfamily, which   
are responsible for metabolizing approximately 20% of 
prescribed drugs [52], are also valuable candidates for 
pharmacogenetic applications. CYP2C9 is responsible for 
metabolism of drugs such as glipizide, tolbutamide and 
warfarin, the oral anticoagulant of choice to treat and prevent 
thrombotic disease in South Africa. Functional alleles that 
reduce the clearance of warfarin may result in higher 
bleeding risk and thus require lower dosage, however these 
alleles need to be considered in combination with VKORC1 
(vitamin K epoxide reductase complex, subunit 1) variants. 
The VKORC1 protein is inhibited by warfarin, therefore 
decreasing the amount of vitamin K available as a co-factor 
for clotting proteins. Thus, genetic variants affecting 
VKORC1 will have an impact of warfarin response [53, 54]. 
Currently, the US Food and Drug Administration (FDA) 
recommends genetic testing and subsequent dosage adjust- 
ments prior to warfarin treatment. The recommended range 
of expected therapeutic warfarin doses based on CYP2C9 
and  VKORC1  genotypes, however, usually only includes 
VKORC1 -1639G>A (rs9923231) and 1173 C>T (rs9934438) 
and  CYP2C9*2 and *3 variants, which are prevalent   
in Caucasian and Asian populations [55]. Unfortunately, 
specific guidelines based on genotypes prevalent in African 
populations are lacking. The CYP2C9*5, *6 and *9 alleles 
were detected in the Venda population [56] while these three 
alleles, as well as CYP2C9*3,  *8 , *11  and *31 were 
identified by Mitchell et al. [54]. The latter cohort comprised 
of 213 individuals (including 100 controls and 113 patients 
taking warfarin) from the South African Black population 
from the Johannesburg region (no ethnic group specified). 
Interestingly,  CYP2C9*3 and *5 were not detected in   
a Ghanaian population [57], but *3 was detected in an 
Ethiopian population [58], while *5 was detected in a 
Beninese population [59], indicative of the fact that African 
populations cannot be treated as one unit. Twenty six novel 
CYP2C9 variants, as well as three known VKORC1 variants 
(rs72547529, rs7200749 and rs7294), were also detected in 
the South African cohort studied by Mitchell et al. [54]. The 
latter study furthermore determined how 11 CYP2C9 and 
two VKORC1 variants, present at allele frequencies of  0.02 
in their cohort, influence warfarin dosage variability. It was 
concluded that the CYP2C9 and VKORC1 variants, along 
with a small subset of environmental factors, account for 
45% of warfarin dosage variability. More specifically, it was 
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CYP2C9*2  and  *3, occurred at frequencies <0.005 in the 
African population in South Africa and may therefore be of 
little value to pharmacogenetic tests in this population, 
additional variants not included in these guidelines were 
associated with warfarin variability in this population. Three 
CYP2C9  variants (*8, and two novel SNPs, g16179 and 
g46028) were associated with decreased warfarin dosage   
and two VKORC1  variants (rs7200749 and rs7294) were 
associated with increased warfarin dosage and should there- 
fore be included in South African warfarin dosage guidelines. 
However, before these guidelines are implemented, more 
genetic variation detection and prospective clinical studies 
are required, especially because VKORC1 variants -1639G> 
A and 1173 C>T, the major determinants of dose
 variability 
related to VKORC1  [60],  were not included in Mitchell’s 
study [54].  
CYP2C19 
  Another member of the CYP2C subfamily, CYP2C19, 
metabolizes drugs used in the treatment of malaria, 
HIV/AIDS, depression and thromboembolic diseases  and 
genetic variants have been implicated in ADRs and treatment 
failure [9]. Of these gene-drug interactions, the CYP2C19-
clopidogrel interaction has recently been ranked as one of the 
most important for pharmacogenetic applications [61] and 
individuals carrying the CYP2C19*2 allele are more likely to 
experience a cardiovascular ischemic event or death [62]. 
Data on genetic variants in the CYP2C19 gene in Coloured, 
Xhosa and Venda populations revealed that the majority of 
individuals could be classified as IMs [47, 56, 63, 64]. 
Striking differences in the frequencies of the four CYP2C19 
metabolizer classes were noted when comparing Coloured 
and Xhosa populations to each other, but also to international 
Asian and Caucasian populations [64]. Important alleles such 
as CYP2C19*2 and the African specific *9 were detected in 
the Coloured, Xhosa and Venda populations at comparable 
frequencies, but *17 has only been genotyped in the Xhosa 
and Coloured populations. The CYP2C19*17 allele has been 
associated with an improved response to clopidogrel, but 
also with an augmented risk of bleeding [9, 65]. The non-
functional CYP2C19*3, which is absent in the majority of 
African populations and present in higher frequencies in 
Asian populations, was only present in the Coloured 
population [64], reflecting the high level of admixture in   
this population. Two novel alleles (CYP2C19*27 and *28) 
were also identified in the Xhosa and Coloured cohorts in  
the latter study. In vitro studies showed that CYP2C19* 
27 may cause a decrease in expression of downstream   
coding sequences. CYP2C19*28  was present at very low 
frequencies in the Xhosa and Coloured populations, 
indicating the importance of identifying novel and rare 
variants in South African populations.  
CYP2D6 
  CYP2D6 is responsible for the metabolism of appro- 
ximately 25% of all prescribed medications, including anti- 
depressants, antipsychotics, antiarrhythmics, anticancer 
agents and opioid analgesics, such as codeine and morphine 
[66]. The CYP2D6 gene is known to be highly polymorphic, 
with variable allele frequencies in different populations   
[67, 68]. The most comprehensive studies on allelic variation 
in South African populations were performed in the Coloured 
[69], Venda [47, 56] and Xhosa populations [70]. Resequencing 
and genotyping have revealed a rich allelic diversity, 
including non-functional alleles as well as novel alleles   
in the Coloured (CYP2D6*64, *65 and *66) and Xhosa 
(CYP2D6*73 and *74) populations. All three populations 
had a high prevalence of the reduced function CYP2D6*17 
and  *29 alleles, explaining in part the high incidence of   
IMs seen in these and other African populations [56, 71]. 
Interestingly, both the Coloured and Xhosa control 
populations exhibited a very high CYP2D6*5 (gene deletion) 
allele frequency (Coloured = 17.2%, Xhosa = 14.2%), while 
the frequency of this allele was reported to be 5% in the 
Venda population [47, 63, 69, 70]. The allele frequencies 
reported for the Coloured and Xhosa populations also 
differed notably from the Venda for other alleles, such   
as  CYP2D6*10 (Table 2), as well as from other African 
populations [68]. Results from a study by Wright et al. [70] 
showed that at least 12.5% of the Xhosa cohort, representing 
the extreme ends of the CYP2D6 phenotypic classes, would 
most likely benefit from pharmacogenetic testing prior to the 
treatment with medication metabolized by CYP2D6. 
CYP3A4 and CYP3A5 
  The CYP3A family of enzymes, including CYP3A4 and 
3A5, is involved in the metabolism of more drugs than any 
other biotransformation enzymes [72]. The CYP3A family is 
also known for its large inter-individual variation in enzyme 
expression, due to a combination of environmental and 
genetic factors [73]. Adult CYP3A activity is largely 
determined by genetic variants in CYP3A4 and/or CYP3A5, 
as active metabolism of the one can compensate for defective 
metabolism of the other [74]. Numerous drugs are meta- 
bolized by CYP3A4, including calcium channel blockers, 
erythromycin, local anaesthetics and the large majority of 
non-nucleoside reverse transcriptase and protease inhibitors 
for ART [75]. The best characterized variant in CYP3A4 is 
probably the -392A>G polymorphism, the key variant of 
haplotype CYP3A4*1B. The frequency of the -392G allele in 
indigenous South African populations from the KwaZulu-
Natal (mainly Zulu [76]) and Western Cape provinces 
(Xhosa [46]) (see Fig. 1, Table 2) is similar to that of other 
African populations (69-82%) [77-79]. Chelule et al. [76] 
also determined the frequency of this variant in Indian (11%) 
and Caucasian (57%) ethnic groups from the KwaZulu-Natal 
province of South Africa. The frequency reported for this 
Caucasian cohort was much higher than that reported for   
a Caucasian population from the Western Cape province   
[80] and other Caucasian populations, i.e. 2-10% [72, 81]. 
The frequency of CYP3A4*1B  reported for the Coloured 
population varied from 21.2% [80] to 57.1% [46]. Dis- 
crepancies in allele frequencies reported for the Coloured 
population may illustrate different percentage contributions 
from the ancestral populations [34, 36], and will always 
complicate the use of an average population frequency for 
many genetic variants in this population. Fernandez et al. 
[80] also noted that the variant -392G-allele was associated 
with an increased susceptibility to developing prostate cancer 
in both Coloured and Caucasian cohorts from the Western 
Cape, similar to findings in the African American population 
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  CYP3A5 is the major P450 enzyme in the esophagus, 
and polymorphisms in CYP3A5 have been proposed as risk 
factors for esophageal cancer, which is highly prevalent 
among African males in South Africa [83]. CYP3A5*3, 
resulting in severely decreased enzymatic activity,  was 
detected in the Xhosa, Coloured and Caucasian populations 
at markedly different frequencies [80, 84] (Table 2). Another 
allele, CYP3A5*6, which includes a functionally significant 
polymorphism giving rise to absence of activity, is the most 
common defective allele in the African (Xhosa) population, 
but is less prevalent in the Coloured population [84] (Table 
2). The frequency of CYP3A5*3 in other African populations 
is 12-15%, and the frequency for CYP3A5*6 is 14-16%   
[78, 79]. The African specific allele, CYP3A5*7, is rare   
in the Xhosa and Coloured populations [84]. Notably, the 
frequency of *3 was significantly higher in the Coloured 
control population, compared to oesophageal cancer patients 
from the same population group (P=0.025) [84], while no 
statistically significant difference in allele frequencies was 
seen between controls and patients with prostate cancer from 
this population [80].  
3.2. Other Pharmacogenes 
ABCB1 
  ABCB1 ( MDR1), member 1 of subfamily B of the 
adenosine triphosphate-binding cassette (ABC) genes, 
encodes P-glycoprotein (P-gp). P-gp exhibits broad substrate 
specificity and plays an important role in the trans-
membrane transport of numerous therapeutic drugs [85]. 
Furthermore, P-gp is clinically relevant due to its central role 
in: (i) multi-drug resistance, and (ii) drug-drug interactions 
[86]. There is significant variability in the ABCB1 SNP and 
haplotype frequency distribution among different ethnic 
populations [85]. Although association between genetic 
variation and phenotype (including P-gp expression, activity 
and drug response) remains largely inconclusive [87], 
genetic profiling of this important pharmacogene should 
eventually be considered in pharmacodiagnostic tools.  
  Allele frequencies for the most extensively studied 
polymorphism in the ABCB1 gene, 3435C>T, vary 
substantially between Caucasians (50%) and Ghanaians (10-
11%) [79, 88]. Varied frequencies are also evident in South 
Africa for African, Coloured, Indian and Caucasian popula- 
tions [46, 76] (Table 2). While ABCB1 variants, 1236C>T 
and 2677G>T/A, were not detected in Ghanaians [79], these 
two variants, as well as the -129T>C variant, were detected 
in HIV patients of the Xhosa and Coloured populations [46]. 
These authors found a significant association between the -
129T>C and 2677G>A genotypes and immune recovery in 
response to ART [46].  
NAT1 and NAT2 
  Genetic variants in N-acetyltransferase (NAT) genes, 
such as NAT1 and NAT2, affect specific activity of the 
encoded enzymes that results in slow or rapid acetylation of 
the drugs that they metabolize, leading to toxic side effects 
or drug inefficacy. A total of 25.7% putative slow NAT1 
genotypes were detected in 101 African individuals, the 
majority of which were Tswana speaking from the North 
West province [89]. This cohort also displayed high genetic 
diversity for NAT2, which corresponds to NAT2 genotyping 
studies in the Venda population [47, 90]. The frequencies of 
the four slow acetylation NAT2 alleles, *5, *6, *7 and *14 
were lower in the Xhosa population, compared to the Venda 
population, with the African specific NAT2*14 being 
fourfold more prevalent in the Venda than in the Xhosa [90, 
91] (Table 2). A new allele, NAT2*6E, was also reported at a 
frequency of 8% in the Venda population, corresponding to 
the frequencies found in Zimbabweans and Tanzanians [90]. 
Rapid  NAT1  and  NAT2 genotypes were present at a 
significantly higher frequency in the African population from 
South Africa compared to a Caucasian cohort from the 
United Kingdom (UK) [89]. The authors consequently 
assumed that the significant differences in NAT genotypes 
could contribute to the distinctive cancer morbidity and 
mortality pattern seen in the African populations in South 
Africa. Furthermore, in a review paper on NAT2 poly- 
morphisms and their effect on isoniazid treatment in TB 
patients, the role that slow acetylation alleles could play in 
patient compliance, isoniazid-toxicity and the emergence of 
drug-resistant strains of mycobateria, is emphasized [14]. 
TPMT 
  TPMT (thiopurine S-methyltransferase) is responsible for 
catalyzing the S-methylation of thiopurines such as 6-
mercaptopurine and azathioprine [92], which are immuno- 
suppressant drugs. The value of this gene for pharmaco- 
genetics is highlighted by the fact that it was one of the first 
genes for which guidelines for dosing were given by the 
Clinical Pharmacogenetics Implementation Consortium [92]. 
Additionally, a recent study has found a compelling associa- 
tion with the TPMT  variant, rs12201199, and cisplatin-
induced hearing loss [93]. Heckmann et al. [94] investigated 
the relationship between azathioprine toxicity and TPMT 
genotype in a South African cohort and reported that 
heterozygosity of TPMT*3A and TPMT*3C was significantly 
associated with haematological toxicity (P=0.012) and 
hepatotoxicity (P=0.005). Of the three alleles investigated, 
TPMT*2  was absent in all three of the South African 
populations (African, Coloured and Caucasian) and TMPT* 
3A  and  TPMT*3C  were present at very low frequencies. 
Interestingly, investigation of TPMT activity showed 
differences between the ethnic groups, such that the African 
controls exhibited lower activity than the activity previously 
reported for African Americans, which was similar to that of 
the Coloured individuals. These findings correlate to the fact 
that both the South African Coloured and African American 
populations are highly admixed and may have similar 
ancestry components. With regard to cisplatin-induced 
hearing loss, although no studies examining the associated 
variant have been reported in South African individuals, the 
frequency of rs12201199 is ten times higher in Yoruban 
individuals from Nigeria when compared to Caucasian 
individuals from Utah [95], therefore further examination is 
warranted in African individuals. 
  From the examples discussed here, it is clear that the 
limited number of South African populations studied to date 
display distinctive genetic profiles, emphasizing the require- 
ment for appropriate genotyping platforms to adequately 
capture the genetic diversity in each population. It is already Pharmacogenomic Research in South Africa  Current Pharmacogenomics and Personalized Medicine, 2011, Vol. 9, No. 3    199 
evident that some of the populations, such as the Xhosa and 
Coloured populations, need to be considered independently. 
Preliminary data on these two populations analyzed with a 
custom pharmacogenetic SNP array has further substantiated 
this finding for other genes, not discussed in this section 
[42]. However, more extensive genetic diversity studies in 
geographically/culturally isolated populations are warranted 
to determine to what extent the different African populations 
differ from each other (e.g. Nguni from the Sotho language 
group). Often studies simply refer to a “Black South 
African” or “African” populations without specifying the 
specific ethnic group. Likewise, data for different South 
African populations, including African, Coloured, Caucasian 
and Asian/Indian individuals are often pooled [96]. From the 
examples given in the preceding section, it is clear that such 
studies do not contribute adequately to the identification of 
the unique genetic profiles of our diverse populations. 
Knowledge of the full spectrum of genetic diversity in   
these populations is a prerequisite for clinical application   
of pharmacogenomics in South Africa. Estrella et al. [97] 
have illustrated that “skin color correlates poorly with 
genetic ancestry and, by extension, poorly represents the 
pharmacogenetic diversity” within the Brazilian population, 
with African, European and Amerindian ancestry. Often   
this is also true for our populations, especially for the 
Coloured population, where significant variation in   
ancestry proportions between individuals is evident [34, 36]. 
These unique genetic profiles bring unique challenges,   
but also unprecedented  opportunities for developing and 
implementing pharmacogenomic testing and novel drug 
development. 
4. THE NEXT PHASE OF PHARMACOGENOMIC 
RESEARCH IN SOUTH AFRICA  
  Future South African genomic research, including studies 
of pharmacogenomic nature, should focus on the diagnosis, 
prevention and treatment of the major communicable and 
non-communicable diseases in the country. Such research 
needs to be carefully planned to enable the efficient use of 
limited funding and thus help address the disparity in the 
number of genomic studies that have already been performed 
in this and other African countries [98]. As discussed in the 
preceding sections, most of the pharmacogenetic research in 
South Africa has been performed on single candidate genes 
and baseline allele frequencies have been determined for a 
handful of pharmacogenes in a few populations. Future 
studies focusing on the country’s populations should aim to 
bring the field into the genomic era of research. In order to 
achieve this goal and to ensure sustainable research in 
pharmacogenomics in South Africa, particular attention 
should be given to three key areas with regards to genomic 
study design: (i) the extension of existing and the establish- 
ment of new national and international multi-disciplinary 
collaborations, consortia and research networks, (ii) the 
collection and storage of relevant biological samples in bio-
repositories, including thoroughly assessed clinical and demo- 
graphic data, and (iii) the careful evaluation of strategies and 
methodology that should be used in order to ensure novel 
research that contributes to the field on a global level. 
  The advent of genomic technologies, such as DNA micro- 
arrays and next generation sequencing, has revolutionized 
the number of genetic variants/regions that can be studied in 
a short amount of time in a single study. However, with this 
increased number of associations comes the substantial 
problem of multiple testing [e.g.,  P  values of <5x10
-8 are 
generally required for significance in genome-wide 
association studies (GWAS)]. This is especially problematic 
for genomic studies of complex traits and diseases, where the 
effect size of individual genetic polymorphisms is likely to 
be small [99]. Cohorts of thousands of samples are required 
in such studies in order to obtain adequate statistical power 
to detect positive associations. It is therefore important to 
form strong collaborations with fellow research groups, 
especially those on the African continent, to help in the 
assembly of large cohorts of patient samples and population 
matched controls. This is an area that has been inadequately 
addressed in the past, with poor communication between 
African research groups. From a pharmacogenomic point of 
view, collecting cohorts of patients on the same treatment 
regime is particularly challenging and sometimes requires 
the collection of samples from numerous study sites. Setting 
up research consortia and networks similar to the National 
Institutes of Health (NIH) Pharmacogenomics Research 
Network [100] would make the organization of such studies 
more streamlined. This would also ensure that strong 
proposals can be drafted and subsequently used to provide 
research that is relevant to the South African community and 
other African populations.  
  The collection and storage of biological specimens in 
bio-repositories is imperative for efficient genomic research, 
as well as for the future of personalized medicine. Not only 
do bio-repositories aid in generating large numbers of 
samples for these types of research, but they also increase 
collaborative potential, as resources can be combined or 
shared nationally and internationally between bio-
repositories [101]. Matimba et al. [47] reported on an 
initiative to establish a biobank of samples from African 
populations and emphasized its potential for pharmaco- 
genomic applications by reporting on pharmacogenetically 
relevant alleles in nine ethnic groups from five African 
countries. Only one South African population group, the 
Venda, was included in this preliminary report. Future 
endeavors should attempt to perform comprehensive 
sampling of the diverse South African populations, and 
should include patient cohorts. 
  Large scale genomic studies in South Africa should 
analyze phenotypes that place the highest burden on local 
health care systems, such as those discussed in preceding 
sections. Findings from these studies could stratify particular 
local populations into groups or subpopulations that share a 
particular genomic risk marker, which could receive a 
different therapeutic intervention. Additionally, it is impor- 
tant that there are clear guidelines for the assessment of 
phenotypes before sample collection commences. A clear 
illustration of this can be found in GWAS of type 2 diabetes. 
Genetic variation in the FTO  (fat mass and obesity-
associated) gene is a confirmed risk factor for the 
development of type 2 diabetes, with risk most probably 
being mediated through body mass [102]. Meta-analyses of 
type 2 diabetes GWAS data have shown that this association 
was not detected in studies where obesity was an exclusion 
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of phenotype is therefore important for future studies in 
South African populations to prevent phenotypic hetero- 
geneity and allow for the generation of robust findings.  
  To avoid potential pitfalls, genomic research in gene- 
tically unique and diverse South African and African 
populations should involve a distinct set of methodological 
considerations. The type of platform used to perform 
research is of particular importance in this regard. Although 
commercial genotyping arrays are improving with regard to 
the amount of genome-wide variation that is captured, they 
should still be used with caution in African populations. In 
the same way that incomplete clinical data can affect the 
results of GWAS, incomplete allele coverage can have a 
comparable effect [104]. There are a number of commercial 
arrays available that have been designed especially for 
pharmacogenomic applications [e.g., AmpliChip (Roche), 
DMET (Affymetrix), ADME core (Illumina)], yet even these 
platforms may not be adequate for pharmacogenomic appli- 
cations in South African populations [64, 70]. Additionally, 
genotype-phenotype discordance appears to present more 
frequently in subjects of recent African diaspora when 
compared to Caucasian individuals and may be partially 
explained by rare or African-specific genetic variation [56, 
71]. Ultimately, however, if genetic variation is adequately 
captured, African populations offer the advantage of 
allowing for fine mapping of GWAS signals and the 
subsequent identification of actual “causal variants”, due to 
the low LD observed in their genomes [104].  
  The goal of obtaining a thorough catalogue of genetic 
variation present in African populations is being aided by 
large scale population-based resequencing endeavors such as 
the 1000 Genomes Project [105], which will allow for the 
design of more comprehensive microarrays. Unfortunately, 
no genomes from the United Nations sub region, “southern 
Africa”, are currently included in the 1000 Genomes Project 
or the HapMap3 Project [106]. Sequencing technologies can 
be effectively used in South African populations to capture 
the unique genetic variation present in these individuals. 
Limited targeted resequencing of candidate pharmacogenes 
has often been used to reveal unique genetic variants [56, 64, 
70], while whole genome sequencing results are also 
available for one South African genome [28]. 
  Next generation sequencing already has applications in 
pharmacogenomic research [107], and by implementing the 
capture of targeted regions such as the exome (~180  000 
exons), rapid and cost effective alternatives to genome 
sequencing are being provided. Investigating the coding 
regions allows for the identification of polymorphisms that 
have a large effect on protein function and therefore 
represent relatively low hanging fruits in this type of 
research. Current pharmacogenomic studies that employ 
such technologies should perhaps select samples at the 
extreme ends of the phenotypic spectrum to improve the 
chances of finding positive associations, with relatively 
strong effect sizes. However, as the cost of sequencing 
rapidly decreases [108], analysis of large numbers of whole 
genome sequences, which are the gold standard in genomic 
research, should become financially viable in the near future.  
  Finally, since the majority of diseases that require urgent 
attention in South Africa are complex disorders, often 
entailing multi-facetted treatment, it is important that high 
standard genomics studies are performed so that they can be 
integrated into holistic or systems biology approaches.   
Such approaches would entail the simultaneous considera- 
tion of the various ‘omic’ disciplines (e.g., transcriptomics, 
proteomics, metabolomics and epigenomics) to elucidate 
novel pathways for therapeutic targets as well as to shed 
light on gene networks associated with disease and/or drug 
response [109, 110]. This highlights the inadequacies of the 
majority of candidate gene studies and demonstrates that 
future genomic studies need to accurately dissect the 
intricate nature of complex disorders in order to facilitate 
translational research.  
5. ETHICAL, LEGAL AND SOCIAL ISSUES (ELSI) 
  As argued in preceding sections, the endeavor to include 
South African populations in future genomic research is   
vital for the successful application of pharmacogenomics 
within the country. It is important though that individuals 
and communities consenting to partake in research are 
recognized as key partners and not merely as resources   
for the research. Furthermore, they should be protected   
from potentially negative outcomes emanating from these 
studies.  
  Ethical and social challenges encountered with genomic/ 
pharmacogenomic research in South Africa are very similar 
to those encountered by other developing countries [111]. 
Practical issues such as language barriers should also be 
considered, and to enable proper communication between 
researchers and participants, the latter should receive 
comprehensive information and informed consent documents 
in their home language, particularly if they are not fluent in  
a second language. Furthermore, researchers should be 
sensitive and respectful to social and cultural differences 
between communities and should incorporate the customs 
and beliefs of the participants into their research design 
[112].  
  To quote Nhlanhla Mhkize [113], “Investigators, 
therefore, must understand that traditional conceptions of 
medicine and disease employ dual understandings”, 
including both “physical and psychic components”. In South 
Africa it has been estimated that approximately 80% of the 
population visit the 200,000 to 350,000 traditional healers 
practicing in the country [114]. Although indigenous 
medicine may be perceived to conflict with “western” 
medicine, traditional healers are a highly valuable asset to 
the country. Researchers from the University of KwaZulu-
Natal have initiated a program to train traditional healers in 
HIV prevention, counseling and care [115]. Thus, by 
harnessing the abilities of traditional healers to bridge 
cultural gaps between western and African customs and 
medicine, a much needed and trusted source of emotional/ 
spiritual care for terminally ill patients is provided, which 
works in unison with a western therapeutic approach. By 
using regional social structures and systems as channels of 
communication between researchers and participants, 
community engagement is encouraged. This should also   
help to create a “sense of research ownership by the 
communities” [116]. Although much can be learnt from 
projects such as HapMap 1/2/3 [106] and MalariaGen [117] 
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developing world context, every research project will bring 
its unique challenges, and ELSI should therefore feature 
strongly on the agenda of any genomic/pharmacogenomic 
research project. 
  As has already been highlighted by this article, South 
Africa is a country which is rich in cultural and genetic 
diversity. However, coupled with the obvious benefits 
associated with this diversity, is the potential for exploita- 
tion, particularly since the human and technological 
resources that are required to analyze this material on a 
grand (genomic) scale still remain underdeveloped in the 
country. This situation is aggravated by limited national 
legislation governing the harvesting, storage, analysis and 
export of human genetic/genomic material [118].  
  The notion of genomic sovereignty is rapidly gaining 
prominence in the local and international community and its 
inclusion in both local and international legislation is seen as 
an urgent requirement to prevent exploitation of the 
populations that are being researched by those from outside 
the country. Genomic sovereignty is the capacity of a people, 
a country or nation to own and to control both access to   
and use of, samples, data and knowledge concerning or 
emanating from genomic material [119]. This definition 
pertains to genetic material of human, animal and plant 
origin. Two areas have been given particular attention, 
namely access and benefit sharing. 
  The notion of access defines the need for local 
populations to have access to data that is generated from 
their genetic/genomic material. The disease profile in South 
Africa is characterized by very specific ethnic/racial 
differences, including for example diabetes, obesity, hyper- 
tension and hyperlipidemia [7, 120-124]. Since the combina- 
tion of local environmental conditions, coupled with genetic 
predisposition to certain diseases, will impact on the 
incidence/prevalence of the disease, it goes without saying 
that any genetic/genomic data that emerges from studies on 
indigenous populations should be made available to those 
populations to allow strategies for prevention, diagnosis and 
treatment of the relevant diseases to be developed. This in 
turn will affect public health policies and the attribution of 
national/health budgets in a more cost-effective manner. 
  The notion of benefit sharing requires that some form of 
financial or social benefit is returned to the population from 
which the genetic material was derived [125]. Although 
benefit sharing arrangements may be complex and 
challenging, it is essential that both the communities and 
their governments are involved in these discourses [126]. In 
South Africa, benefit sharing is covered in the case of plants 
and animals in Chapter 6 of the Biodiversity Act (no. 10 of 
2004) [127]. However, there is at present no reference in any 
South African legislation to the notion of benefit sharing (or 
to access for that matter) regarding human material. For 
many years, genetic material has been leaving South Africa 
to be analyzed outside of the country. In many cases, neither 
the principles of access or benefit sharing have been 
respected. With regard to the former, once data derived from 
this material is published in the public domain, it does 
become accessible. However, this is by default, and no 
specific attention is given to returning it to the community 
from which it was derived. This is particularly important 
when drug clinical trials have a significant pharmaco- 
genomic component. In this case, a large amount of very 
important information is generated in laboratories outside the 
country, and very rarely does this find its way back into the 
country to be utilized for the benefit of the indigenous 
populations from which it was derived. Benefit may take the 
form of financial benefit, social benefit (housing, schools, 
healthcare facilities, etc.) and also scientific capacity 
development. 
  What are the solutions to these problems? First, the 
notion of genetic sovereignty needs to be debated more 
widely in open public fora – both nationally and inter- 
nationally. Lobby groups need to be formed to ensure that 
exploitation is prevented and that the principles of access and 
benefit sharing are respected.  
  Second, measures need to be put into place to regulate 
and monitor the flow of genetic/genomic material into and 
out of the country. Despite the current absence of specific 
legislation in this regard, regulation and monitoring can be 
achieved in two ways. This includes; (i) Research Ethics 
Committees insisting that these matters are given attention in 
projects that involve human genetic/genomic material, and 
(ii) the National Department of Health insisting on the same 
requirements in export permits that are issued for material 
that leaves the country. Currently applications for such 
permits require very little information.  
  Third, human capacity development is a critical issue that 
could be addressed as part of a benefit-sharing arrangement 
with companies/institutions/individuals that work on South 
African genetic/genomic material beyond our borders. One 
of the areas that requires particular attention is the 
development of bioinformatics skills, in order to address the 
computational and statistical bottlenecks associated with the 
analysis of the vast amounts of data generated from genomic 
research, which is seen as a national priority (National 
Biotechnology Strategy for South Africa [21]). It is 
important that locally generated research is used to train 
South African scientists and that intellectual property is 
appropriately managed in order to build the required 
resources within the country.  
  Fourth, South Africa is currently revising the section 
(Chapter 8) of the National Health Act (no. 61 of 2003) 
which deals with “Control of use of blood, blood products, 
tissue and gametes in humans” [118]. Chapter 8 has to date 
not been promulgated, and this part of the legislation is 
currently covered by the largely outdated Human Tissue Act 
(no. 65 of 1983) [128]. The current process of revision 
should be used to address the legislative gap with respect to 
human genetic/genomic material. 
  Many of the recommendations listed above are of course 
transferable to other developing countries that are exposed  
to similar universal problems of unidirectional flow of 
information and potential exploitation. Thus, it is hoped   
that South Africa can in the future serve as a reference for 
developing countries for the successful implementation   
of ethical, legal and social considerations of genomic 
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6. PHARMACOGENOMIC STUDIES IN SOUTH 
AFRICA: CHALLENGES AND OPPORTUNITIES IN 
AN AFRICAN CONTEXT 
  Although the benefits of the Human Genome Project are 
beginning to be realized, there has been a skewed 
distribution in terms of where related research has been 
carried out. Thus far, the majority of completed genomic 
research studies (75%) have been conducted exclusively in 
populations of European descent while very few have been 
done in Africa or on Africans [98], despite the fact that 
Africa carries a disproportionately large burden of avoidable 
diseases, including infectious diseases as well as an alarming 
increase in non-communicable diseases [8]. Ironically, the 
high prevalence of communicable and non-communicable 
diseases in South Africa offers great opportunities for 
genomic research. Vast numbers of patients from diverse 
populations are available for epidemiological and clinical 
studies, also suited for numerous clinical trial designs, which 
can be combined with genomic or pharmacogenomic studies. 
The diverse populations of the country offer a variety of 
advantages. While the high allelic diversity and short areas 
of LD in African populations allow fine mapping of loci, the 
highly admixed Coloured and homogenous Afrikaner and 
Indian populations permit other mapping strategies. 
Additionally, ideal opportunities for genotype-phenotype 
correlation studies exist, as the genetically diverse 
populations can be used to assess the influence of genetic 
variation on phenotypes in similar environments, as well as 
in different environments (e.g., rural versus urban). These 
studies could also provide opportunities for epigenetic 
studies.  
  Examples of research opportunities that are ripe in South 
Africa as a result of these unique disease cohorts, include the 
study of genes that are associated with viral infection (and 
HIV in particular), progression to the AIDS defining illness, 
overall survival, mother to child transmission, as well as 
ART response. Outstanding work in this regard is already 
being done in South Africa for HIV/AIDS (e.g., [129-132]) 
and TB (e.g. ([133-135]), and a number of large well defined 
cohorts have already been collected (e.g. [133, 136, 137]). 
Some of these cohorts provide ample opportunities for 
clinical trails that can also be utilized for pharmacogenomic 
studies.  
  Study design is of paramount importance for the success 
of any research that may be implemented within South 
Africa. A recent paper outlined the types of pharmaco- 
genomic design that could provide a good guideline for the 
types of patient cohorts that need to be assembled in order to 
generate evidence for pharmacogenomics in clinical practice 
[138]. For example, the incorporation of pharmacogenomic 
analyses during preclinical and clinical trials could aid in 
translating genomic discoveries to health care; verifying the 
clinical validity and utility of genomic findings is thus 
another important focus area for future research. Currently 
there is a paucity of prospective genomic studies as well as 
large scale randomized controlled trials in South Africa and 
the rest of the continent, therefore these aspects need to be 
addressed.  
  Many more unexplored opportunities for pharmacogenetics/ 
genomics studies exist [139], of which oncology is one. 
Cancer is the leading cause of death worldwide [140] and the 
incidence of this disease is gathering momentum in 
developing countries such as South Africa. The importance 
of pharmacogenomic strategies that can be implemented for 
effective treatment of the disease is substantiated by the 
number of oncology guidelines from both the FDA and 
European Medicines Agency (EMA), many of which refer to 
tumor-specific pharmacogenetics [141, 142]. When referring 
to the application of cancer pharmacogenomics it is essential 
to make the distinction between germ-line and tumor-
specific mutations. Both are important, but while the former 
relies on determining the baseline frequencies of variation  
in different ethnic groups, the latter is dependent on the 
disease. FDA and EMA clinically validated tumor/disease-
specific variants can therefore be applied in local treatment 
strategies. 
  One of the main obstacles to large scale genomic or 
pharmacogenomic studies within South Africa is limited 
funding for research and development purposes [22]. 
However, new prospects in this regard have recently arisen 
with a number of new initiatives, of which three are 
discussed here, namely the Human Health and Heredity in 
Africa (H3Africa), the Southern African Human Genome 
Program (SAHGP) and the Pharmacogenetics for Every 
Nation Initiative (PGENI). These initiatives aim, among 
other things, to characterize African genomic variation as 
well as to determine the baseline frequencies of known 
variation. The genetic variation detected by the H3Africa and 
SAHGP will be used to aid in the understanding of disease 
pathogenesis and thereby improve the ability to diagnose, 
treat and prevent the diseases and disorders which affect 
Africans, while the PGENI data will be used for pharmaco- 
genetic applications on a global level. Through the imple- 
mentation of these initiatives, it is hoped that we can 
influence public health policy, and also improve the 
infrastructure, human resources and public awareness in 
genomic research in Africa.  
  H3Africa consists of a consortium of African scientists 
who, with the assistance of well established international 
partners such as the Wellcome Trust in the UK and the NIH 
in the US, aims to bridge the research, expertise and 
infrastructural genomic gap that Africa faces. This genomic 
research endeavor realizes that the documentation of human 
genome variation cannot be completed unless Africa and its 
genetically diverse people are involved. Therefore, this 
initiative aims to facilitate the integration of research based 
on the latest genomic technologies in order to create and 
sustain a network of African centers which will provide 
training, research and clinical services, with the ultimate goal 
of improving health outcomes and research in Africa [143].  
  When considering the execution and application of 
genomic or pharmacogenomic research in an African 
context, South Africa is one of the countries that is best 
equipped to accommodate this research. Besides the high 
burden of disease which South Africa shares with other 
African countries, the country has one of the best health 
systems on the continent, including health statistics, and   
is regarded as the frontrunner for biomedical research in 
Africa [144]. Upcoming initiatives can quickly and easily 
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strengthening is needed in terms of expertise (bioin- 
formaticists, statisticians, biologists, bio-ethicists) and 
infrastructure, possibly due to the relatively strong economy 
and stable administration of the country [143]. The SAHGP 
was recently launched with the specific goal of under- 
standing DNA variation in southern Africans [145]. This 
project is aimed at forming collaborations between scientists, 
government and industry to build capacity for genomic 
research, to institute sustainable resources for this research, 
including a bio-repository and database, and to “translate the 
information and knowledge into improvements in human 
health”. The issue of genomic sovereignty, including benefit 
sharing, will also be carefully considered.  
  The South African government has shown interest in 
genomic and biotechnology endeavors and the DST already 
has a National System of Innovation in place which is 
involved in a ten year plan, focused on moving South 
Africa’s economy from resource-based to knowledge-based. 
One of the grand challenges proposed in this plan is the 
“farmer to pharma” challenge which aims to place South 
Africa as a leader in biotechnology and pharmaceutical 
industries in the developing world [21]. 
  With regard to genomics education, the Public 
Understanding of Biotechnology program of the DST and 
the Human Genome Education Institute, a virtual entity that 
is involved in bridging the gap between researchers and the 
lay public by way of offering public seminars on topics with 
a leaning towards genomics, is already established. Further- 
more institutes such as the South African National Bioinfor- 
matics Institute (SANBI), to give one example, are in place 
to provisionally address issues regarding the generation of 
high throughput genomic data and the bioinformatic analyses 
thereof. 
  Of specific relevance to the field of pharmacogenetics is 
PGENI, which has been set-up with the main objective of 
integrating pharmacogenetics into public health care for all 
global populations. PGENI aims to determine the baseline 
frequencies of known DNA variants present in 154 genes 
which are involved with the action of 206 drugs. Populations 
from 104 countries around the world will be examined,   
of which South Africa is one of the nine regional centers  
and is therefore responsible for facilitating collaborations 
between the surrounding PGENI countries [146]. This again 
highlights the promise of South African genomic research. 
  Projects such as the H3Africa Initiative, the SAHGP and 
PGENI should play an integral role in the coordination of 
genomic research in South Africa, but also other African 
countries, by providing infrastructure and capital to local 
researchers, as well as providing aid in addressing the 
computational and statistical bottlenecks encountered at 
present.  
CONCLUSIONS AND OUTLOOK 
  South Africa has a turbulent history and has witnessed 
numerous struggles, but the current battle against the force 
majeure of communicable and non-communicable diseases 
is one of the fiercest yet, placing a heavy burden on its 
people. Furthermore, to date, drugs have primarily been 
designed to suit the specific needs of Caucasian and Asian 
populations and only 1% of the newly developed drugs are 
focused on the treatment of disease affecting poor countries 
[147]. In this paper we have argued that the implementation 
of pharmacogenomic research may play a valuable role in 
refining current treatment regimes in the country. It may be 
debated that such research is “too late” for South Africa, or 
that it is too technologically advanced and not cost-effective. 
However, with the exciting and promising advent of high-
throughput sequencing and new initiatives such as the 
SAHGP and H3Africa, it seems more likely that not only are 
we “just in time” [16], but we could assume a place in the 
global genomic research community.  
  In order for pharmacogenetic/genomic biotechnologies to 
be successful in South Africa, the highly diverse populations 
making up the Rainbow Nation need to be comprehensively 
characterized, and research, which has previously focused   
on candidate genes, needs to move into the genomic   
arena. However, before South Africa embarks on its pharma- 
cogenomic venture, there are several aspects that need to be 
addressed and accompanied with appropriate guidelines. 
Amongst others, the establishment of extensive bio-
repositories will require clear guidelines that will ensure   
that participants are informed and protected, such that   
data is only utilized for the specified research purposes 
[148]. Furthermore, the development of extensive multi-
disciplinary collaborative networks will ensure that samples 
in bio-repositories are utilized to their full potential. Such 
collaborations need to consider the benefit of all participants, 
but should also be aimed towards capacity building and take 
genomic sovereignty into account. Researchers should 
preferably take a holistic view on personalized medicine and 
should move beyond a purely genetic approach to include all 
aspects of treatment response, incorporating initiatives such 
as the Human Proteome Project [149] into research projects. 
Additionally the manner in which results are reported is 
equally important, as reliable and complete results can be 
used for reviews and meta-analyses and ultimately create a 
strong evidence base for translation into the clinical setting 
[150]. This is essential as only 3% of global genomic 
research moves beyond gene discovery [151]. Downstream 
applications derived from research may include diagnostic 
tests and development of new therapeutics. However, it is 
vital that these outputs benefit the South African public and 
promote local research, while taking intellectual property 
rights, ELSI and cultural aspects into consideration [152]. In 
addition to expert knowledge, public engagement in pharma- 
cogenomics is another important aspect, for example, as   
a means to bring together different forms of knowledge   
and “ways of knowing” to the fore, including tacit and   
local knowledge from the citizens and patients [153-155]. 
Although it is clear that much needs to be done before 
pharmacogenetics/genomics is successfully implemented 
within the South African context, success in this domain   
will not only contribute to the country’s knowledge-based 
economy, but will also enhance its position as a global 
research and development partner.  
  In the past, South Africa has surprised the world on more 
than one occasion by making the seemingly impossible, 
possible. Hopefully, in the future, we will be able to look 
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towards building a viable and successful national pharmaco- 
genomics program. Success in this arena will also allow 
South Africa to act as a model for building capacity in the 
rest of Africa, to aid in the much needed improvement of 
patient treatment throughout the continent.  
ABBREVIATIONS  
ABC =  Adenosine  triphosphate-binding  cassette 
ADRs  =  Adverse drug reactions 
ART =  Anti-retroviral  therapy 
CNV  =  Copy number variation 
CYP =  Cytochrome  P450   
DST  =  Department of Science and Technology 
ELSI  =  Ethical, Legal and Social Issues 
EM  =  Extensive metabolizers  
EMA =  European  Medicines  Agency 
FDA  =  Food and Drug Administration 
GWAS =  Genome-wide  association  studies 
H3Africa  =  Human Health and Heredity in Africa 
HIV/AIDS  =  Human Immunodeficiency Virus/Acquired 
Immunodeficiency Syndrome 
IM  =  Intermediate metabolizers  
LD  =  Linkage disequilibrium  
mtDNA =  Mitochondrial  DNA 
NAT =  N-acetyltransferase 
NIH  =  National Institutes of Health  
P-gp =  P-glycoprotein   
PGENI  =  Pharmacogenetics for Every Nation 
Initiative 
Pharmacogene  =  Pharmacogenetically relevant gene  
PM  =  Poor metabolizers  
SAHGP  = Southern African Human Genome Pro- 
gram 
SANBI  = South African National Bioinformatics 
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TB =  Tuberculosis 
UK =  United  Kingdom 
UM =  Ultrarapid  metabolizers 
US =  United  States 
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